ES2535437T3 - Métodos para tratar el mieloma múltiple utilizando terapias combinadas basadas en anticuerpos anti-CS1 - Google Patents

Métodos para tratar el mieloma múltiple utilizando terapias combinadas basadas en anticuerpos anti-CS1

Info

Publication number
ES2535437T3
ES2535437T3 ES07840746.7T ES07840746T ES2535437T3 ES 2535437 T3 ES2535437 T3 ES 2535437T3 ES 07840746 T ES07840746 T ES 07840746T ES 2535437 T3 ES2535437 T3 ES 2535437T3
Authority
ES
Spain
Prior art keywords
huluc63
bortezomib
dose
patients
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07840746.7T
Other languages
English (en)
Spanish (es)
Inventor
Daniel Afar
Kenneth C. Anderson
Yu-Tzu Tai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
AbbVie Biotherapeutics Inc
Original Assignee
Dana Farber Cancer Institute Inc
AbbVie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38831279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2535437(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dana Farber Cancer Institute Inc, AbbVie Biotherapeutics Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of ES2535437T3 publication Critical patent/ES2535437T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
ES07840746.7T 2006-08-07 2007-08-07 Métodos para tratar el mieloma múltiple utilizando terapias combinadas basadas en anticuerpos anti-CS1 Active ES2535437T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83618506P 2006-08-07 2006-08-07
US836185P 2006-08-07
US94426207P 2007-06-15 2007-06-15
US944262P 2007-06-15
PCT/US2007/075403 WO2008019378A1 (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Publications (1)

Publication Number Publication Date
ES2535437T3 true ES2535437T3 (es) 2015-05-11

Family

ID=38831279

Family Applications (2)

Application Number Title Priority Date Filing Date
ES07840746.7T Active ES2535437T3 (es) 2006-08-07 2007-08-07 Métodos para tratar el mieloma múltiple utilizando terapias combinadas basadas en anticuerpos anti-CS1
ES13168383.1T Active ES2589302T3 (es) 2006-08-07 2007-08-07 Métodos de tratamiento de mieloma múltiple utilizando terapias de combinación basadas en HuLuc63 con bortezemib

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13168383.1T Active ES2589302T3 (es) 2006-08-07 2007-08-07 Métodos de tratamiento de mieloma múltiple utilizando terapias de combinación basadas en HuLuc63 con bortezemib

Country Status (23)

Country Link
US (4) US8632772B2 (OSRAM)
EP (5) EP2068874B1 (OSRAM)
JP (1) JP5340935B2 (OSRAM)
CN (1) CN101686971B (OSRAM)
AU (1) AU2007281684C1 (OSRAM)
BR (1) BRPI0716647A2 (OSRAM)
CA (1) CA2660356C (OSRAM)
CY (5) CY1116247T1 (OSRAM)
DK (2) DK2641601T3 (OSRAM)
ES (2) ES2535437T3 (OSRAM)
HR (2) HRP20150449T1 (OSRAM)
HU (4) HUE029027T2 (OSRAM)
IL (2) IL196919A (OSRAM)
LT (4) LT2641601T (OSRAM)
LU (3) LU93276I2 (OSRAM)
MX (1) MX2009001441A (OSRAM)
NL (1) NL300840I2 (OSRAM)
NO (1) NO346835B1 (OSRAM)
NZ (1) NZ574978A (OSRAM)
PL (2) PL2641601T3 (OSRAM)
PT (2) PT2641601T (OSRAM)
SI (2) SI2068874T1 (OSRAM)
WO (1) WO2008019378A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500370A (ja) 2006-08-07 2010-01-07 ピーディーエル バイオファーマ，インコーポレイティド 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法
HUE029027T2 (en) 2006-08-07 2017-01-30 Abbvie Biotherapeutics Inc Procedures for Multiple Myeloma Treatment Using HuLuc63 and Bortezomib Combination Therapies
JP2011523560A (ja) 2008-06-02 2011-08-18 ダナ−ファーバー キャンサー インスティテュート インク． Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
NZ589880A (en) 2008-06-16 2012-10-26 Immunogen Inc Use of synergistic anti-cancer compositions comprising lenalidomide, at least one corticosteroid and at least one immunoconjugate
PE20120059A1 (es) * 2008-10-21 2012-02-27 Onyx Therapeutics Inc Combinaciones farmaceuticas con epoxicetonas peptidicas
EP2476438B1 (en) * 2009-09-10 2014-07-23 Kyowa Hakko Kirin Co., Ltd. Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4)
CA2780998C (en) * 2009-11-24 2016-07-12 Celgene Corporation Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
CN105377288B (zh) 2012-11-05 2019-11-15 达纳-法伯癌症研究所股份有限公司 Xbp1、cd138和cs1肽的组合物制备药物的用途
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2015069785A1 (en) * 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
CA2924268C (en) * 2013-11-21 2021-05-18 F. Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
LT3182996T (lt) * 2014-08-22 2023-03-10 Celgene Corporation Daugybinės mielomos gydymo būdai imunomoduliuojančiais junginiais derinyje su antikūnais
WO2016049022A1 (en) * 2014-09-23 2016-03-31 Board Of Trustees Of Michigan State University Compositions and methods for modulating an immune response
WO2016054354A1 (en) 2014-10-02 2016-04-07 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
WO2016070089A2 (en) 2014-10-31 2016-05-06 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
US10302644B2 (en) 2014-11-04 2019-05-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
BR112017011538A2 (pt) * 2014-12-04 2018-03-13 Bristol-Myers Squibb Company combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)
HRP20210552T1 (hr) 2015-05-13 2021-05-14 Morphosys Ag Liječenje multiplog mijeloma (mm)
ES2886657T3 (es) * 2015-06-29 2021-12-20 Bristol Myers Squibb Co Regímenes de dosificación inmunoterapéutica que comprenden pomalidomida y un anticuerpo anti-CS1 para el tratamiento de cáncer
CN109432398A (zh) * 2016-03-13 2019-03-08 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
SG11201907923VA (en) 2017-03-29 2019-09-27 Agency Science Tech & Res Anti oligosaccharide antibody
JP2021504475A (ja) * 2017-11-22 2021-02-15 ヒルストリーム・バイオファーマ・インコーポレイテッド ボルテゾミブを含むポリマーナノ粒子
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
KR20220092578A (ko) 2019-11-05 2022-07-01 브리스톨-마이어스 스큅 컴퍼니 M-단백질 검정 및 이의 용도
CN115368462A (zh) * 2022-07-19 2022-11-22 合肥天港免疫药物有限公司 双特异性抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112969A (en) 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
WO1996037208A1 (en) 1995-05-25 1996-11-28 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CA2752140A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
EP1824513A4 (en) * 2004-11-04 2010-06-09 Fibron Ltd TREATMENT OF B-CELL TUMORS
JP2010500370A (ja) 2006-08-07 2010-01-07 ピーディーエル バイオファーマ，インコーポレイティド 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法
HUE029027T2 (en) 2006-08-07 2017-01-30 Abbvie Biotherapeutics Inc Procedures for Multiple Myeloma Treatment Using HuLuc63 and Bortezomib Combination Therapies
US20080095768A1 (en) 2006-08-07 2008-04-24 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells

Also Published As

Publication number Publication date
PT2641601T (pt) 2016-10-14
IL196919A0 (en) 2009-11-18
NO346835B1 (no) 2023-01-23
EP2641601B8 (en) 2016-09-21
CN101686971B (zh) 2013-09-11
JP2010500371A (ja) 2010-01-07
HUS1600043I1 (hu) 2016-12-28
EP2641600A1 (en) 2013-09-25
CY2016038I1 (el) 2017-07-12
HUS1600044I1 (hu) 2016-12-28
AU2007281684C1 (en) 2013-12-19
IL196919A (en) 2016-03-31
WO2008019378A1 (en) 2008-02-14
DK2068874T3 (da) 2015-04-27
US8632772B2 (en) 2014-01-21
LTPA2016031I1 (lt) 2016-11-10
NL300840I2 (OSRAM) 2017-01-03
ES2589302T3 (es) 2016-11-11
LT2641601T (lt) 2016-10-10
NO20090968L (no) 2009-04-30
HRP20150449T1 (xx) 2015-06-05
US20080152646A1 (en) 2008-06-26
EP2641601B1 (en) 2016-07-06
AU2007281684A1 (en) 2008-02-14
CY2016036I1 (el) 2017-07-12
CY1117992T1 (el) 2017-05-17
LTPA2016029I1 (lt) 2016-11-10
LTPA2016030I1 (lt) 2016-11-10
SI2641601T1 (sl) 2016-11-30
LTC2068874I2 (lt) 2018-11-12
CA2660356A1 (en) 2008-02-14
AU2007281684B2 (en) 2013-05-16
EP3115049A1 (en) 2017-01-11
LU93277I2 (fr) 2016-12-27
SI2068874T1 (sl) 2015-06-30
DK2641601T3 (en) 2016-08-22
CY2016036I2 (el) 2017-07-12
LU93276I2 (fr) 2016-12-27
CA2660356C (en) 2016-04-05
NZ574978A (en) 2012-08-31
CN101686971A (zh) 2010-03-31
HRP20161284T1 (hr) 2016-12-16
LU93275I2 (fr) 2016-12-27
EP2068874B1 (en) 2015-01-28
EP2942057A1 (en) 2015-11-11
IL243933A0 (en) 2016-04-21
EP2641601A1 (en) 2013-09-25
HK1129853A1 (en) 2009-12-11
CY2016037I1 (el) 2017-07-12
HUS1600045I1 (hu) 2016-12-28
US20140322201A1 (en) 2014-10-30
CY1116247T1 (el) 2017-02-08
MX2009001441A (es) 2009-07-06
PT2068874E (pt) 2015-05-21
HUE029027T2 (en) 2017-01-30
JP5340935B2 (ja) 2013-11-13
US20160137735A1 (en) 2016-05-19
US20170342150A1 (en) 2017-11-30
BRPI0716647A2 (pt) 2017-05-16
PL2641601T3 (pl) 2017-01-31
PL2068874T3 (pl) 2015-06-30
EP2068874A1 (en) 2009-06-17

Similar Documents

Publication Publication Date Title
ES2535437T3 (es) Métodos para tratar el mieloma múltiple utilizando terapias combinadas basadas en anticuerpos anti-CS1
Sun et al. Resveratrol suppresses the growth and metastatic potential of cervical cancer by inhibiting STAT3Tyr705 phosphorylation
AU2010223058A1 (en) Kinase protein binding inhibitors
BR112021010789A2 (pt) Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar
KR20140079831A (ko) 췌장암 및／또는 담도암 치료약
KR20230066401A (ko) 항종양 치료법에서 면역 체크포인트 억제제와 조합된 치아우라닙의 용도
US20190241660A1 (en) Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer
US20230130403A1 (en) Methods of treatment with s1p receptor modulators
Okuma et al. Disseminated herpes zoster infection initially presenting with abdominal pain in patients with lymphoma undergoing conventional chemotherapy: a report of three cases
Holliday et al. Osteoclast polarization and orthodontic tooth movement
Faulkner et al. Reactive Angioendotheliomatosis Following Ad26. COV2. S Vaccination.
US20230094843A1 (en) Pharmaceutical combination for treating tumors and application thereof
WO2020236890A1 (en) Treating chronic liver disease
CN110776521A (zh) 一种1,2,4-三唑-1,3,4-噻二唑类化合物及其应用
Lerner et al. Beneficial response of cervical dystonia spasmodic torticollis to cidofovir, an acyclic phosphonate analog (s-1-3-hydroxy-2-phosphonylmethoxypropyl) of cytosine
HK1233169A (en) Combination therapies based on anti-cs1 antibodies for treating multiple myeloma
CN118340763A (zh) Salvigenin在制备治疗急性髓系白血病药物中的应用
CN101919861A (zh) 苯甲酰胺衍生物在制备治疗艾滋病药物中的应用
HK1189515A (en) Methods of treating multiple myeloma using combination therapies based on huluc63 with bortezomib
HK1189516A (en) Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
HK1129853B (en) Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
CN101919846A (zh) N2,n5-双[2-(3,4-二甲氧苯基)乙基]-2,5-吡啶甲酰胺的药物应用
CN101890002A (zh) 一种苯丙噻吩衍生物在制备抗艾滋病毒药物中的应用